GSK Quits Trade Group BIO as Industry Faces Uncertain Political ... - dofaq.co
GSK Quits Trade Group BIO as Industry Faces Uncertain Political ...
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return
Relation's $45 million upfront GSK collaboration all part of right technology, right biology, right time
GSK Executives Acquire Shares Under Reward Plan
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade (NYSE:GSK)
Vaccine stocks hit by Robert Kennedy Jr nomination
Pharma shares hit as Trump picks RFK Jr to lead health department
Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
GSK Withdraws Jesduvroq From the US Market
Moderna Fires Back With Counterclaims In GSK RSV Vax Suit
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK Inks Two Deals with Relation for Fibrotic Diseases and Osteoarthritis
'It's the biology, stupid': Relation and GSK team up on fibrosis, osteoarthritis
Statement: Zantac (ranitidine) litigation – settlement agreements reached
GSK Turns Back to China in Another Potential $1B+ ADC Deal
Apprentice programmes
